REFERENCES 14. Apt L, Isenberg SJ, Yoshimori R, et al.
The effect of
1. Murthy GV, Vashist P, John N, Pokharel G, Ellwein LB.
Prevelence and causes of visual impairment and blindness
in older adults in an area of India with a high cataract
surgical rate. Ophthalmic Epidemiol 2010;17(4):185–195.
2. Gilbert C. New issues in childhood blindness. Community
Eye Health 2001;14:53–56.
3. Gogate P, Kalua K, Courtright P. Blindness in childhood
in developing countries: time for a reassessment? PLoS
Med 2009;5(12):e1000177.
4. Houang ET, Gilmore OJ, Reid C, Shaw EJ. Absence of
bacte- rial resistance to povidone iodine. J Clin Pathol
1976;29(8): 752–755.
5. Apt L, Isenberg SJ, Yoshimori R, Spierer A. Outpatient
topical use of povidone-iodine in preparing the eye for sur-
gery. Ophthalmology 1989;96(3):289–292.
6. Isenberg SJ, Apt L, Yoshimori R, Pham C, Lam NK.
Efficacy of topical povidone-iodine during the first week
after ophthalmic surgery. Am J Ophthalmol
1997;124(1):31–35.
7. Isenberg SJ, Apt L, Wood M. A controlled trial of
povidone- iodine as prophylaxis against ophthalmia
neonatorum. N Engl J Med 1995;332(9):562–566.
8. Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of
povidone-iodine to treat infectious conjunctivitis in
children. Am J Ophthalmol 2002;134(5):681–688.
9. DiLoreto DA Jr, Bressler NM, Bressler SB, Schachat AP.
Use of best and final visual acuity outcomes in
ophthalmological research. Arch Ophthalmol
2003;121(11):1586–1590.
10. Jabs DA. Improving the reporting of clinical case series.
Am J Ophthalmol 2005;139(5):900–905.
11. Schreier H, Erdos G, Reimer K, Konig B, Konig W,
Fleischer W. Molecular effects of povidone-iodine on rele-
vant microorganisms: an electron-microscopic and
biochem- ical study. Dermatology 1997;195(Suppl
2):111–116.
12. Pels E, Vrensen GF. Microbial decontamination of human
donor eyes with povidone-iodine: penetration, toxicity,
and effectiveness. Br J Ophthalmol 1999;83(9):1019–
1026.
13. Apt L, Isenberg S, Yoshimori R, Paez JH. Chemical
prepara- tion of the eye in ophthalmic surgery. III. Effect
of povidone- iodine on the conjunctiva. Arch Ophthalmol
1984;102(5): 728–729.
povidone-iodine solution applied at the conclusion of
ophthalmic surgery. Am J Ophthalmol 1995;119(6):701–
705.
15. Isenberg SJ, Apt L, Yoshimori R, Leake RD, Rich R.
Povi- done-iodine for ophthalmia neonatorum
prophylaxis. Am J Ophthalmol 1994;118(6):701–706.
16. Hale LM. The treatment of corneal ulcer with povidone-
iodine (Betadine). N C Med J 1969;30(2):54–56.
17. Schuhman G, Vidic B. Clinical experience with
povidone- iodine eye drops in patients with conjunctivitis
and kerato- conjunctivitis. J Hosp Infect 1985;6(Suppl
A):173–175.
18. Katz J, Khatry SK, Thapa MD, et al. A randomised trial
of povidone-iodine to reduce visual impairment from
corneal ulcers in rural Nepal. Br J Ophthalmol
2004;88(12): 1487–1492.
19. Gregori NZ, Schiffman JC, Miller DM, Alfonso EC.
Clinical trial of povidone-iodine (Betadine) versus
placebo in the pre- treatment of corneal ulcers. Cornea
2006;25(5):558–563.
20. Melki SA, Safar A, Yaghouti F, et al. Effect of topical
povidone-iodine versus topical ofloxacin on experimental
Staphylococcus keratitis. Graefes Arch Clin Exp
Ophthalmol 2000;238(5):459–462.
21. Sharma LG, Goyal JK, Sharma U, Chandak GK, Nepalia
LK. Evaluation of topical povidone-iodine versus
gentamycin in staphylococcus coagulase positive corneal
ulcers–an experi- mental study. Indian J Ophthalmol
1990;38(1):30–32.
22. Michalova K, Moyes AL, Cameron S, et al. Povidone-
iodine (betadine) in the treatment of experimental
Pseudomonas aeruginosa keratitis. Cornea
1996;15(5):533–536.
23. Berkelman RL, Holland BW, Anderson RL. Increased
bacte- ricidal activity of dilute preparations of povidone-
iodine solu- tions. J Clin Microbiol 1982;15(4):635–639.
24. Benevento WJ, Murray P, Reed CA, Pepose JS. The
sensi- tivity of Neisseria gonorrhoeae, Chlamydia
trachomatis, and her- pes simplex type II to disinfection
with povidone-iodine. Am J Ophthalmol
1990;109(3):329–333.
25. Parmar P, Salman A, Kalavathy CM, Kaliamurthy J,
Thomas PA, Jesudasan CA. Microbial keratitis at
extremes of age. Cornea 2006;25(2):153–158.
26. Srinivasan M, Mascarenhas J, Rajaraman R, et al.
Corticoste- roids for bacterial keratitis: the Steroids for
Corneal Ulcers Trial (SCUT). Arch Ophthalmol
2012;130(2):143–150.
Goldstein MH, Kowalski RP, Gordon YJ. Emerging
fluoroqui- nolone resistance in bacterial keratitis: a 5-year
review. Ophthalmology 1999;106(7):1313–1318.
27. Sharma V, Sharma S, Garg P, Rao GN. Clinical
resistance of Staphylococcus keratitis to ciprofloxacin
monotherapy. In- dian J Ophthalmol 2004;52(4):287–
292.
28. Ly CN, Pham JN, Badenoch PR, et al. Bacteria
commonly isolated from keratitis specimens retain
antibiotic susceptibil- ity to fluoroquinolones and
gentamicin plus cephalothin. Clin Experiment
Ophthalmol 2006;34(1):44–50.
29.
Parmar P, Salman A, Kalavathy CM, et al.
Comparison of topical gatifloxacin 0.3% and
ciprofloxacin 0.3% for the treatment of bacterial
keratitis. Am J Ophthalmol 2006; 141(2):282–286.
30. Chaurasia S, Ramappa M, Ashar J, Sharma S.
Neonatal infec- tious keratitis. Cornea
2014;33(7):673–676.
Hernandez-Camarena JC, Graue-Hernandez EO, Ortiz-
Casas M, et al. Trends in microbiological and antibiotic
sensi- tivity patterns in infectious keratitis: 10-year
experience in Mexico City. Cornea 2015;34(7):778–785